ReviewAnnals of medicine2026
Role of the WNT signalling pathway in physiological and pathological blood-brain barrier.
Review in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe blood-brain barrier (BBB) is essential for maintaining central nervous system (CNS) homeostasis and protecting neural tissue. The wingless-type MMTV integration site family (WNT) signalling pathway has emerged as a key regulator of BBB development, maintenance, and repair. Dysregulation of this pathway is implicated in BBB dysfunction associated with various neurological disorders.
methodsWe conducted a comprehensive review of recent literature integrating data from animal models, human induced pluripotent stem cell (iPSC)-derived BBB systems, and disease-specific mechanistic studies. The role of canonical and non-canonical WNT signalling in BBB formation, maturation, and pathological alteration was systematically analyzed.
resultsWNT7a/b ligands activate β-catenin-dependent signalling to drive cerebral angiogenesis and BBB differentiation, with G protein‑coupled receptor 124 (GPR124), Reversion‑inducing cysteine‑rich protein with Kazal motifs (RECK), and SRY‑related HMG‑box transcription factor 17 (Sox17) identified as critical co-regulators. In the mature BBB, WNT activity is suppressed epigenetically to maintain barrier stability. In diseases such as ischaemic stroke, Alzheimer's disease, multiple sclerosis, and glioblastoma, WNT signalling is disrupted, leading to BBB breakdown. Pharmacological activation of WNT/β-catenin signalling (e.g. lithium, Glycogen synthase kinase 3β (GSK-3β) inhibitors and engineered WNT ligands) restores BBB integrity in preclinical models. Additionally, modulation of WNT signalling can enhance drug delivery across the BBB, offering therapeutic advantages in brain tumours and neurodegenerative diseases.
conclusionsWNT signalling is a central molecular axis governing BBB integrity under both physiological and pathological conditions. Targeted modulation of this pathway represents a promising therapeutic strategy for restoring BBB function and improving CNS drug delivery. Further mechanistic and translational studies are warranted to advance clinical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.